The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia

Ferens Unit, Middlesex Hospital Outpatients Department, London, UK.
Disability and Rehabilitation (Impact Factor: 1.99). 02/1997; 19(1):20-5. DOI: 10.3109/09638289709166441
Source: PubMed


This study investigates the impact of Botox injections on speech disability in a group of patients with adductor spasmodic dysphonia. Patient-perceived disability was assessed on the Speech Disability Questionnaire. A factor analysis on speech disability yielded five factors. Four of these, social isolation (p < 0.001), negative communication (p < 0.005), public avoidance (p < 0.05) and limited understanding (p < 0.01), showed significant change from prior to and one week post injection. Speech and language therapists' assessment also showed changes in voice quality over the same period. These findings are discussed in terms of the relationship between voice quality, disability and handicap, in adductor spasmodic dysphonia.

14 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.
    Clinical Neuropharmacology 09/2004; 27(5):234-44. DOI:10.1097/01.wnf.0000145508.84389.87 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to examine the psychosocial consequences of BOTOX (Allergan, Inc. Irvine, CA) treatment for spasmodic dysphonia (SD). This article also explores how patients judge the success of treatment and make decisions about future treatment based on psychosocial issues relevant to them. This study follows the phenomenological tradition of qualitative inquiry in which the objective is to explore the lived experiences of a group of persons who share a common phenomenon, in this case receiving BOTOX injections for SD. Six adults with SD who had been receiving BOTOX injections on a long-term basis participated in face-to-face interviews. The interviews were recorded, transcribed, and analyzed according to phenomenological guidelines to identify consistent themes as well as differences among participants' experiences. The results are summarized in three primary themes that suggest (1) participants' experiences vary over time based on changes in factors such as lifestyle and personal priorities; (2) BOTOX has multidimensional psychosocial implications in physical, personal, and social domains; and (3) participants individualize their treatment regimens, taking into consideration the burden of treatment, scheduling priorities, and other strategies to maximize the benefits of BOTOX. Based on this study, suggestions are provided for future research into a psychosocial outcome measurement, including longitudinal evaluations that accommodate changing patient priorities over time; multidimensional evaluations that incorporate physical, personal, and social issues; evaluations that include a measure of the burden of treatment; and evaluations that support a shared decision-making model with the voice clinicians.
    Journal of Voice 04/2007; 21(2):231-47. DOI:10.1016/j.jvoice.2006.01.007 · 1.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coping is a key concept in psychological medicine, which refers to the way in which people deal with the stress of illness. Voice disorders may have pervasive effects upon the individual's life beyond the vocal impairment yet, there is little reference in current literature as to how people cope with voice problems. This study explored and validated the Voice Disability Coping Questionnaire (VDCQ), a newly developed disease-specific coping measure, which elicits how patients cope with voice problems. Eighty subjects presenting with muscle tension dysphonia (MTD) and adductor spasmodic dysphonia (ASD) completed a 28-item VDCQ as part of an initial assessment protocol before intervention, within a longitudinal study. Principal component analyses were used to investigate the underlying structure of this questionnaire; analyses of variance were used to determine group differences in coping strategies. The principal component analyses generated four coping subscales: "social support," "passive coping," "avoidance," and "information seeking" measured over 15 items. The subscales revealed logical correlations between them. Avoidance and passive coping were found to be used by the ASD group significantly more than the MTD group. This study provided initial evidence for the validity and reliability of the VDCQ; it differentiated between clinical groups and may facilitate a patient-centered approach, which enhances the understanding of voice disorders.
    Journal of voice: official journal of the Voice Foundation 07/2008; 23(2):209-17. DOI:10.1016/j.jvoice.2007.09.001 · 0.94 Impact Factor
Show more